What Is Palynziq?
Palynziq is an FDA-approved medication for phenylketonuria (PKU). PKU is an inherited metabolic disorder that impairs the body's ability to process phenylalanine (Phe), an essential amino acid. Without strict dietary control, Phe can accumulate in the blood and brain, potentially leading to severe cognitive deficits.
Palynziq is administered via injection. Clinical trials have explored a dosing approach involving the delivery of gradually increasing doses over several hours, aiming to reach a cumulative dose equal to a patient's reactive dose. This method helps manage potential hypersensitivity reactions (HSRs) that could otherwise lead to treatment interruption or dose reduction. The initial administration of Palynziq often occurs under medical supervision, following a Risk Evaluation and Mitigation Strategy (REMS) protocol.
Currently, Palynziq is being investigated in clinical trials for phenylketonuria, with a total of 2 trials involving 54 participants. These studies began as early as 2020 and are planned to continue until at least 2025.
Uses and Conditions Under Study
Palynziq is currently under investigation for the treatment of phenylketonuria (PKU). PKU is an inherited metabolic disorder where the body cannot effectively break down phenylalanine (Phe), an essential amino acid found in many protein-rich foods. Without stringent dietary management, Phe can accumulate in the blood and brain, leading to severe cognitive deficits. Achieving metabolic control, defined as maintaining Phe levels within a healthy range, is crucial for individuals with PKU.
The clinical trials for Palynziq focus on its potential to help patients with PKU manage their blood phenylalanine levels and achieve this metabolic control. By addressing the impaired metabolism of Phe, Palynziq aims to mitigate the adverse effects associated with high Phe concentrations. Studies are exploring different aspects of the drug's administration and its impact on patients' metabolic control, particularly in those who may not respond adequately to other treatments.
A total of 2 clinical trials are currently examining Palynziq for conditions related to PKU, including Phenylketonuria and Phenylketonurias. These studies have collectively enrolled 54 participants. The first trial began on May 27, 2020, and the latest trial is expected to conclude by January 17, 2025. One of these trials is actively recruiting new participants.
Sponsors for these investigations include BioMarin Pharmaceutical, an industry sponsor, and Emory University, an academic institution.
Dosing
Palynziq is administered by injection. The dosage form studied in clinical trials is referred to as Reactive Dose Delivery (RDD). This approach involves the gradual delivery of increasing doses of Palynziq over several hours, at fixed time intervals.
The goal of this titration is to reach a cumulative dose that equals the patient's "reactive dose." A reactive dose is defined as the dose at which a hypersensitivity reaction (HSR) occurred, which previously led to an interruption or reduction in treatment dose or frequency. This individualized dosing strategy aims to optimize treatment while managing potential adverse reactions.
Initial injections of Palynziq are typically administered at a clinic, such as the Emory Genetics Clinic, under the direct supervision of a physician. This is in accordance with the Palynziq Risk Evaluation and Mitigation Strategy (REMS) protocol, designed to ensure safe use of the medication. After therapy initiation, patients often continue to monitor their progress by mailing in blood spot filter papers and 3-day dietary records.
Side Effects
The most common side effects reported by patients taking Palynziq (pegvaliase) in clinical trials were joint pain (arthralgia) and reactions at the injection site. In a study, 38% of patients receiving Palynziq experienced arthralgia, compared to 10% of those on placebo. Similarly, 38% of patients on Palynziq had injection site reactions, while only 2% on placebo experienced them.
Other frequently reported side effects included:
- Headache: 35% of patients taking Palynziq, compared to 19% on placebo.
- Anxiety: 28% of patients taking Palynziq, compared to 10% on placebo.
- Hypersensitivity reactions: 27% of patients taking Palynziq, compared to 2% on placebo. These reactions can be serious and include anaphylaxis, which occurred in 10% of patients taking Palynziq and 0% on placebo.
- Nausea: 27% of patients taking Palynziq, compared to 10% on placebo.
- Dizziness: 26% of patients taking Palynziq, compared to 10% on placebo.
- Abdominal pain: 25% of patients taking Palynziq, compared to 10% on placebo.
Patients should discuss any side effects they experience with their healthcare provider.
Clinical Trial Results
Clinical studies have shown that Palynziq (pegvaliase) effectively reduces blood phenylalanine (Phe) levels in adults with phenylketonuria (PKU). Maintaining lower Phe levels is important for managing PKU.
Long-Term Efficacy
In an open-label extension study (PRISM-1) involving 238 patients with PKU, Palynziq significantly reduced blood Phe concentrations over time. The average blood Phe level decreased from 1232.7 micromoles per liter (μmol/L) at the start of the study to 597.1 μmol/L after 12 weeks and further to 296.8 μmol/L after 52 weeks of treatment. Similar sustained reductions were observed in a long-term safety and efficacy study (NCT01815493) involving 197 patients, where average blood Phe levels decreased from 1228.6 μmol/L at baseline to 307.7 μmol/L at Year 1, and remained consistently low at 281.3 μmol/L by Year 4.
Randomized, Placebo-Controlled Study (PRISM-2)
A pivotal Phase 3, randomized, double-blind, placebo-controlled withdrawal study (NCT02612030) evaluated Palynziq in 86 patients who had already achieved blood Phe levels of 600 μmol/L or less while on Palynziq. Patients were either continued on Palynziq (41 patients) or switched to placebo (45 patients) for 8 weeks.
- Blood Phe Levels: At Week 8, patients who continued on Palynziq experienced an average increase in blood Phe of only 15.1 μmol/L. In contrast, patients switched to placebo saw their average blood Phe levels increase significantly by 767.1 μmol/L. This showed a statistically significant difference of 752.0 μmol/L between the groups.
- Treatment Responders: A key measure was the proportion of patients who maintained blood Phe levels at or below 600 μmol/L. 95% of patients who continued on Palynziq met this goal, compared to only 18% of those who switched to placebo.
- Cognitive Function: The study also assessed cognitive function using the PKU-QOL-A questionnaire. Patients continuing Palynziq showed a slight improvement in overall cognitive function, while those on placebo showed a decline. Specifically, for attention, patients on Palynziq had a mean change of -0.1 (indicating improvement or stability), whereas those on placebo had a mean change of +1.5 (indicating decline).
Following the controlled phase, patients who had switched to placebo and then restarted Palynziq in an open-label extension of PRISM-2 (NCT02612030) showed a significant decrease in blood Phe levels, dropping from an average of 1139.1 μmol/L (after placebo) to 300.9 μmol/L after 24 weeks of restarting Palynziq, further demonstrating the drug's effectiveness.
Currently Recruiting Trials
Patients interested in participating in clinical research for Palynziq have an opportunity to join a currently recruiting study. These trials are designed to deepen our understanding of Palynziq's effects and benefits in specific patient populations, contributing valuable insights to its clinical application and patient care.
One such study actively seeking participants is sponsored by Emory University, titled "Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)." This important research is dedicated to exploring how Palynziq affects the nutritional status of individuals living with Phenylketonuria. PKU is a rare, inherited metabolic disorder that prevents the body from properly breaking down phenylalanine (Phe), an essential amino acid found in many foods. If not managed through a stringent, lifelong diet, Phe can accumulate to harmful levels in the blood and brain, potentially leading to significant cognitive deficits and other neurological issues. The primary goal of PKU management is to achieve metabolic control, which involves maintaining Phe levels within a safe range. This study aims to investigate the specific nutritional impacts that Palynziq may have on patients as they strive for this control, offering a deeper understanding of its role beyond just Phe reduction. The trial is targeting an enrollment of 45 participants and is not categorized under a traditional drug development phase, suggesting its focus is on detailed observational or specific impact assessment rather than initial drug efficacy or safety. Individuals interested in learning more about this study can find additional information by referencing its identifier, NCT04404530. Such studies are vital for optimizing treatment strategies and improving patient outcomes.
Where to Participate
Participation in Palynziq clinical trials is currently focused within a specific geographic area. The primary location for the recruiting study is in the United States, offering opportunities for eligible individuals to contribute to this important research.
Currently, the study is being conducted at 2 sites located in Atlanta, Georgia. To be eligible for participation, individuals must be between the ages of 16 and 16 years. The study is open to participants of all genders, and children are eligible to join. It is important to note that healthy volunteers are not being recruited for this trial; participation is specifically for patients with the condition being studied.
Development Timeline
The journey of Palynziq's clinical development began on May 27, 2020, marking the initiation of its first clinical trial. Since then, the development program has involved a total of 2 trials, aiming to enroll 54 participants across these studies. These trials have been supported by two key sponsors: BioMarin Pharmaceutical and Emory University, each contributing to the advancement of understanding Palynziq.
Initially, the research pipeline for Palynziq explored conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia. Over time, the focus expanded to include Phenylketonuria (PKU), reflecting an evolving understanding of the drug's potential applications. The trials have spanned different phases, with one study not specified by phase and another designated as a Phase 4 trial, which typically focuses on post-marketing surveillance and long-term effects. The latest recorded trial activity for Palynziq is noted for January 17, 2025, indicating ongoing research and commitment to its development.